Opinions
Glenn Paradis, BA, CFA
Applera-Celera Gen
CRA-N
DON'T BUY
May 04, 2001
Business model not set out yet. Risky.
$41.000
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
Advertising